AI prediction of response to pre-surgery chemoimmunotherapy for esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort at The Second Xiangya Hospital of Central South University uses multimodal clinical data — including demographics, medical history, imaging, pathology, and laboratory tests — to train deep learning models to predict pathological complete response (pCR) after neoadjuvant chemoimmunotherapy in esophageal cancer. The models will also aim to identify early patients with suboptimal responses (stable disease or progressive disease) prior to surgery. The study uses retrospective clinical and imaging records from patients who received neoadjuvant chemoimmunotherapy and have complete pre- and post-treatment imaging. Models will be developed and internally validated on the institutional dataset to generate predictive tools for potential clinical decision support.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patients with histologically confirmed esophageal cancer based on biopsy results;
2. Patients recommended for neoadjuvant chemoimmunotherapy following multidisciplinary team (MDT) discussion or evaluation by thoracic surgery specialists;
3. Patients who received neoadjuvant chemoimmunotherapy;
4. Patients with complete imaging data before and after neoadjuvant treatment.

Exclusion Criteria:

1. Patients deemed eligible for surgery by the thoracic surgery team but who refused surgical treatment;
2. Patients with missing or poor-quality CT images;
3. Patients with concurrent malignancies other than esophageal cancer;
4. Patients with incomplete clinical data.

Where it's running

• The Second Xiangya Hospital of Central South University
  Changsha, Hunan, China Recruiting

Study contacts

• Study coordinator: Chen Chen
• Email: chenchen1981412@csu.edu.cn
• Phone: +8673185295188

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized Ultrafractionated Stereotactic Radiotherapy with Perioperative FLOT for GEJ and Esophageal Cancer

  This trial tests adding a personalized, ultra-fractionated radiotherapy boost (PULSAR) to standard perioperative FLOT chemotherapy for patients with esophageal or gastroesophageal junction cancer to see if it can be used safely.

  Recruiting Phase 1 University of Texas Southwestern Medical Center · Dallas, Texas · NCT07700420

• Preventing nausea and vomiting during multi-cycle chemo and immunotherapy in esophageal and lung cancer

  This study tests a combination antiemetic with dexamethasone to see if it lowers nausea and vomiting in adults with esophageal or lung cancer receiving several cycles of chemo plus immunotherapy.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07617246

• Ivonescimab plus FOLFOX for advanced HER2-negative stomach and gastroesophageal junction adenocarcinoma

  This study tests whether adding ivonescimab to standard FOLFOX chemotherapy helps people with advanced, HER2-negative stomach or gastroesophageal junction adenocarcinoma as first-line treatment.

  Recruiting at 2 sites Phase 2 Massachusetts General Hospital · Santa Monica, California and 1 other locations · NCT07070466

• 18F-G1 PET/CT to see early immunotherapy response in solid tumors and blood cancers

  We are testing if the 18F-G1 PET/CT scan can help tell early on whether people with solid tumors or blood cancers will respond to immunotherapy.

  Recruiting Peking University First Hospital · Beijing · NCT07039474

• Combining afatinib and palbociclib for previously treated advanced esophageal squamous cell carcinoma

  This trial tests whether taking afatinib together with palbociclib helps control tumor growth in people with recurrent or metastatic esophageal squamous cell carcinoma who have already received prior treatments.

  Recruiting Phase 1/2 West China Hospital · Chengdu, Sichuan · NCT06753747

• Imaging method for digestive system cancer using targeted PET scans

  This study is testing a new type of PET scan to see if it can better help doctors find and diagnose cancers in the digestive system.

  Recruiting RenJi Hospital · Shanghai, Shanghai Municipality · NCT06715839

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.